Karriereverlauf von Jeffrey Greve
Ehemalige bekannte Positionen von Jeffrey Greve
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2018 | 23.08.2022 |
| Gründer | 01.05.2018 | 23.08.2022 | |
Delinea, Inc. (United States)
 Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 | - |
| Gründer | 01.01.2015 | - | |
| ATYR PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.09.2011 | - |
Ausbildung von Jeffrey Greve
| University of Washington | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
- Börse
- Insiders
- Jeffrey Greve
- Erfahrung
